Morgan Stanley Reiterates Overweight Rating on IGM Biosciences (IGMS)
Morgan Stanley analyst Michael Ulz reiterated an Overweight rating and $12.00 price target on IGM Biosciences (NASDAQ: IGMS)The ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)